Safety
Side effects, contraindications, sourcing risk, and practical safety guidance.
47 articlesVIP (Vasoactive Intestinal Peptide) for "Mold Illness": What the Evidence Actually Shows
VIP nasal spray is sold as the capstone treatment in 'mold illness' protocols. The peptide has genuine clinical research behind it, but not for that specific claim.
Read the guide → 🛡 SafetyHow to Read a Peptide Certificate of Analysis: What Third-Party Testing Can (and Can't) Prove
Certificates of analysis are often used to market research peptides as tested or verified. Here's what a COA actually measures, and the real gaps it leaves.
Read the guide → 🛡 SafetyGLP-1 Microdosing: What the Research Actually Shows (and Doesn't)
GLP-1 'microdosing' for energy, longevity, or lower side effects has become a telehealth marketing trend. Here's what the evidence actually supports, and what remains unknown.
Read the guide → 🛡 SafetyGLP-1 Medications and Addictive Behaviors: What the Research Shows
Early research suggests GLP-1 drugs may reduce alcohol, nicotine, and other reward-driven behaviors. Here's what the evidence actually supports, and what's still unproven.
Read the guide → 🛡 SafetyGLP-1 Medications and Dental Health: What the Research Suggests About Dry Mouth and Acid Exposure
GLP-1 drugs don't directly damage teeth, but dry mouth, reflux, and nutrient changes linked to them can raise dental risk. Here's what the evidence shows.
Read the guide → 🛡 SafetyGLP-1 Medications in Type 1 Diabetes: Why Off-Label Use Carries Added Risk
GLP-1 drugs aren't FDA-approved for type 1 diabetes. Some people with type 1 diabetes use them off-label anyway, which raises specific risks around insulin dosing that are worth understanding.
Read the guide → 🛡 SafetyPeptides and Drug Testing: What Anti-Doping Panels Actually Screen For
From growth hormone secretagogues to GLP-1 drugs, peptides occupy very different places on anti-doping prohibited lists. Here's what WADA actually tests for and why some peptides are harder to catch than others.
Read the guide → 🛡 SafetySafe Storage and Disposal of Injectable Peptides: Preventing Accidental Exposure at Home
Injectable peptide medications and sharps need to be stored and disposed of carefully to prevent accidental exposure to children, pets, and others in the household. Here's what general safety guidance covers.
Read the guide → 🛡 SafetyGLP-1 Medications and Blood Pressure: What the Research Shows
Clinical trial data show meaningful drops in blood pressure on GLP-1 and GIP/GLP-1 drugs like tirzepatide, with weight loss explaining most, but not all, of the effect.
Read the guide → 🛡 SafetyGLP-1 Medications and Gallbladder Disease: What the Research Shows About Gallstone Risk
Rapid weight loss and slowed gallbladder motility both raise gallstone risk on GLP-1 drugs. Here's what the trial data actually show, and the warning signs to watch for.
Read the guide → 🛡 SafetyGLP-1 Medications and Exercise: What the Research Shows About Resistance Training and Muscle Preservation
Clinical trials show GLP-1 and dual-agonist drugs cause real lean-mass loss alongside fat loss. Here's what the emerging research on resistance training and protein intake actually shows, and doesn't yet show.
Read the guide → 🛡 SafetyGLP-1 Medications and Fertility: What the Research Shows
What the evidence does and doesn't show about GLP-1 medications, ovulation, contraception, and the so-called Ozempic baby phenomenon.
Read the guide → 🛡 SafetyGLP-1 Medications and MASH: What the Research Shows About Fatty Liver Disease
Semaglutide is FDA-approved for MASH with liver fibrosis, while tirzepatide and survodutide remain investigational for the condition. Here's what the trial data show.
Read the guide → 🛡 SafetyGLP-1 Medications and Cancer Risk: What the Research Shows
What large studies show about GLP-1 medications and obesity-related cancer risk, the thyroid tumor signal behind the black-box warning, and where the evidence is still mixed.
Read the guide → 🛡 SafetyTraveling With Injectable Peptides: TSA Rules and Storage On the Go
Practical, non-medical guidance on TSA rules for traveling with injectable peptide medications, temperature-controlled storage while in transit, and questions to ask your doctor first.
Read the guide → 🛡 SafetyGLP-1 Medications and Diabetic Retinopathy: What the Early-Treatment Risk Curve Shows
Rapid blood sugar improvement from GLP-1 drugs can cause a temporary, well-documented worsening of existing diabetic retinopathy, distinct from the separate NAION eye-safety signal covered elsewhere on this site.
Read the guide → 🛡 SafetyWeight Regain After Stopping GLP-1 Medications: What the Research Shows
Clinical trial data and newer real-world evidence give somewhat different pictures of how much weight people regain after stopping a GLP-1 drug, and why.
Read the guide → 🛡 SafetyGLP-1 Medications and Nutrient Deficiencies: What to Monitor During Rapid Weight Loss
Rapid weight loss from GLP-1 medications can come with reduced food intake and a higher risk of certain nutrient shortfalls. Here's what the research and clinical guidance say to watch for.
Read the guide → 🛡 SafetyGLP-1 Medications and Skin Changes: What the Research Says About "Ozempic Face"
What's actually documented about facial skin laxity and volume loss during rapid GLP-1-related weight loss, and how it differs from a direct drug side effect.
Read the guide → 🛡 SafetyGLP-1 Medications and Breastfeeding: What the Evidence and Guidance Say
Why most clinical guidance still recommends avoiding GLP-1 medications while breastfeeding, and what the evidence actually shows.
Read the guide → 🛡 SafetyGLP-1 Medications and Sleep Apnea: What the SURMOUNT-OSA Research Shows
How Zepbound's FDA approval for obstructive sleep apnea came about and what the trial data actually found.
Read more → 🛡 SafetyGLP-1 Medications and Pediatric Use: What the FDA Approvals Actually Allow
A look at which GLP-1 medications are FDA-approved for use in children and teens, at what ages, for what conditions, and what the evidence gaps are for younger patients.
Read the guide → 🛡 SafetyGLP-1 Medications and Prediabetes: What the Evidence Shows About Preventing Type 2 Diabetes
What SURMOUNT-1 and related trial data show about GLP-1 and dual-agonist medications reversing prediabetes and delaying progression to type 2 diabetes, and where the evidence is still developing.
Read the guide → 🛡 SafetyGLP-1 Medications and Alcohol: What the Research Says About Interactions
What the current research shows about how GLP-1 medications like semaglutide and tirzepatide interact with alcohol, including effects on blood sugar, GI symptoms, and reported changes in alcohol cravings.
Read the guide → 🛡 SafetyGLP-1 Medications and Hair Loss: What the Research Shows
A growing body of research links GLP-1 drugs to higher rates of hair shedding, though researchers still disagree on how much is the drug itself versus rapid weight loss.
Read the guide → 🛡 SafetyGLP-1 Medications and Kidney Health: What the FLOW Trial Shows
Semaglutide's FLOW trial found a 24% reduction in major kidney events in people with type 2 diabetes and chronic kidney disease. Here's what the data shows, and what it means for the drug's FDA-approved uses.
Read the guide → 🛡 SafetyStoring and Handling Injectable Peptides: Temperature, Stability, and Safety Basics
General safety principles for storing and handling injectable peptide products, including temperature sensitivity, warning signs of degradation, and safe disposal.
Read the guide → 🛡 SafetyGLP-1 Medications and Gastroparesis: What the Research Shows About Delayed Gastric Emptying
GLP-1 drugs are designed to slow digestion, but for some patients that effect can become severe enough to resemble gastroparesis. Here's what the evidence shows.
Read the guide → 🛡 SafetyGLP-1 Medications and Eye Health: What the NAION Research Shows
A growing body of research has linked semaglutide and other GLP-1 drugs to a higher relative risk of a rare eye condition called NAION.
Read the guide → 🛡 SafetyGLP-1 Medications and Mental Health: What the Research Says About Suicidality Signals
After early case reports raised concern, the FDA reviewed suicidality data on GLP-1 drugs and moved to remove related warnings in 2026.
Read the guide → 🛡 SafetyGLP-1 Medications and Surgery: What the Anesthesia Guidance Says
GLP-1 drugs delay stomach emptying, which anesthesiologists say raises aspiration risk. Here’s what the current perioperative guidance recommends.
Read the guide → 🛡 SafetyCommon Side Effects of GLP-1 Peptides: Semaglutide and Tirzepatide
The documented common and serious side effects of semaglutide and tirzepatide, based on their FDA-approved labeling.
Read the guide → 🛡 SafetyContraindications for GLP-1 Medications: Who Should Avoid Them
Who should avoid GLP-1 medications like semaglutide and tirzepatide, based on their FDA-approved contraindications.
Read the guide → 🛡 SafetyCounterfeit Peptides: How to Recognize the Warning Signs
How to recognize warning signs of counterfeit peptide products, including fake versions of FDA-approved GLP-1 drugs.
Read the guide → 🛡 SafetyDrug Interactions to Know Before Starting a GLP-1 Peptide
Documented drug interactions with GLP-1 medications like semaglutide and tirzepatide, and why they matter.
Read the guide → 🛡 SafetyGrowth Hormone Secretagogues and Blood Sugar: What to Monitor
Why growth hormone secretagogue peptides can affect blood sugar and insulin sensitivity, and what to monitor.
Read the guide → 🛡 SafetyHow to Talk to Your Doctor About Peptide Therapy
Practical guidance on how to have an honest, productive conversation with your doctor about peptide use, including unapproved peptides.
Read the guide → 🛡 SafetyInjection Site Safety: Reducing Risk With Any Self-Administered Peptide
Practical injection site safety practices for anyone self-administering an injectable peptide, regardless of which compound.
Read the guide → 🛡 SafetyPeptide Cycling and Tolerance: What the Safety Literature Says
What is actually known about peptide cycling and tolerance, and how much of common cycling advice is evidence-based versus anecdotal.
Read the guide → 🛡 SafetyPeptides and Pregnancy: Why the Research Says Avoid
Why GLP-1 and most other peptides are not recommended during pregnancy, based on current research and labeling guidance.
Read the guide → 🛡 SafetySigns of an Allergic Reaction to Injectable Peptides
How to recognize the signs of a mild versus a serious allergic reaction to an injectable peptide, and when to seek emergency care.
Read the guide → 🛡 SafetyThyroid and Pancreatic Risk Warnings for GLP-1 Medications
A closer look at the specific thyroid and pancreatic risk warnings on GLP-1 drug labels, and what the underlying evidence shows.
Read the guide → 🛡 SafetyWhat We Don't Know: Long-Term Safety Data Gaps for Popular Peptides
An honest look at what long-term safety data does and doesn't exist for popular peptides, including newer FDA-approved drugs.
Read the guide → 🛡 SafetyWhen to Stop a Peptide and Seek Medical Care
Concrete warning signs that should prompt stopping a peptide and seeking medical evaluation, across compound categories.
Read the guide → 🛡 SafetyWhy "Natural" or "Research Grade" Labels Don't Guarantee Safety
Why marketing terms like natural and research-grade don't correspond to any regulated safety or quality standard.
Read the guide → 🛡 SafetyWhy Sourcing Matters: Contamination and Purity Risks in Unregulated Peptides
Documented contamination and purity issues found in unregulated peptide products, and why sourcing is a distinct risk from the compound itself.
Read the guide → 🛡 SafetyBone Density and GLP-1 Peptides: What New Research Shows About Fracture Risk
A 2026 study found greater hip bone density loss in GLP-1 users without diabetes than in matched controls. Here's what the data does and doesn't show.
Read the guide → 🛡 SafetyMuscle Loss on GLP-1 Peptides: What the Evidence Shows and How Researchers Are Addressing It
How much of the weight lost on GLP-1 drugs is muscle, what that means clinically, and how amylin combinations and other strategies aim to preserve lean mass.
Read the guide →